Babban Gwajin NAD+ a Cutar Parkinson Ya Bayar da Sakamako Mara Kyau

Nicotinamide riboside (NR), wanda ake sayarwa a matsayin Niagen da Tru Niagen, na ɗaya daga cikin kwayar kariyar rayuwa da suka fi shahara a kasuwa. An gwada shi a cikin mafi girman gwaji da aka gudanar kan cutar Parkinson, wadda take daga cikin cututtukan kwakwalwa, kuma sakamakon da aka samu bai yi daidai da abin da aka yi tsammani ba. A cikin gwajin NOPARK na mataki na uku da aka wallafa a JAMA a watan Oktoba 2026, mutanen da ke da cutar Parkinson a matakin farko waɗanda suka sha NR sun sami ɗan ƙaramin ƙaruwa a alamar ciwo idan aka kwatanta da waɗanda suka karɓi placebo. Tasirin ya kasance ƙanƙanta, amma ya tafi a akasin abin da masana suka yi fatan samu.

Menene Gwajin NOPARK ya Aikata a Zahiri?

NOPARK gwaji ne da aka yi a cikin yanayi na “double‑blind, placebo‑controlled” a mataki na uku, an gudanar da shi a cibiyoyi 11 a Norway.

Wanda aka yi wa gwaji: Mutane manya (shekaru 35 da sama) da aka gano da cutar Parkinson cikin shekaru 2 da suka gabata, matakin Hoehn da Yahr ƙasa da 3, hoton dopamine transporter scintigraphy da ke nuna asarar ƙwayoyin nigrostriatal da ke samar da dopamine, da kuma suna ci gaba da shan magungunan dopamine.
Jimillar masu halarta: An tantance mutane 537, aka zaba 410 daga cikinsu a tsakanin Mayu 2020 da Yuni 2024, kuma an kammala da 393 masu halarta a babban binciken.
Siffofin masu halarta: Matsakaicin shekaru 65.6 (SD 9.4); mata 34 %.
Hanyar magani: NR ta baki 500 mg sau biyu a rana (jimillar 1 000 mg a kowace rana) ko placebo da ya yi kama da shi, tsawon makonni 52.
Matsayin farko (primary endpoint): Canjin jimillar MDS‑UPDRS (sassa I–III) daga lokacin farawa zuwa mako na 52. Ma’aunin yana tsakanin 0–236, inda ƙimar da ta fi girma ke nuni da tsanantar ciwo.

Kammala bin diddigi ya ƙare a Yuni 2025. An rijista gwajin da lambar NCT03568968.

Lambobin da Suka Fito Fili

A mako na 52, a rukunin NR an samu ƙaruwa da 2.45 maki a jimillar MDS‑UPDRS (95 % CI 0.80–4.10), yayin da a rukunin placebo aka samu raguwa da 0.27 maki (95 % CI −1.95 zuwa 1.40).
Bambancin da aka daidaita tsakanin rukuni biyu ya kai 2.72 maki (95 % CI 0.47–4.98; P = .02), wato NR ya ƙara munin alamar ciwo idan aka kwatanta da placebo.
A bangaren alamun da ba na motsa jiki ba (Non‑Motor Symptoms Scale, 0–360), NR ta ƙara 4.22 maki (95 % CI 1.07–7.37; P = .009), wanda ke nuni da tsanantar rashin motsa jiki.

Me Ya Sa “Mummunan” Ke Buƙatar Fahimta

Wannan ba alamar cewa marasa lafiya sun ji raɗaɗi mai tsanani ba. Masu binciken sun yi amfani da minimal clinically important difference (MCID) da aka wallafa don tantance canjin da ke da mahimmanci a kan MDS‑UPDRS: 6.7 maki don inganta da 5.2 maki don ƙara muni. Don haka, bambancin maki 2.72 yana da ƙididdiga mai ma'ana, amma ya kasa cimma iyakar da ake ɗauka a matsayin “ƙara muni”. Ko ma iyakar da masana ke ganin ma'ana, wato 4.98, ba ta kai 5.2 ba.

Daga cikin manyan sakamakon sakandare guda biyar da aka shirya a gaba, huɗu ba su nuna bambanci mai ma'ana ba – wato sassa I, II, III na MDS‑UPDRS da sakamakon hoton dopamine transporter. Abu guda ɗaya kawai da ya bambanta rukuni biyu shi ne sakamakon non‑motor.

Karatu mafi ƙarfi shi ne: NR ba ta ba da wani taimako ba, kuma a maimakon haka ta danganta da ƙarin mummunan sakamako idan aka kwatanta da placebo.

Sauyin Aminci

Wani bincike ya nuna cewa ba a samu ƙaruwa a haɗari masu tsanani a rukuni na NR ba. An samu mutane 17 daga 205 (8.3 %) a ƙungiyar NR da mutane 29 daga 205 (14.1 %) a ƙungiyar placebo da suka fuskanci haɗari masu tsanani. Saboda haka, NR ba ta ƙara haɗari masu tsanani ba – a gaskiya, adadin su ya ƙasa fiye da na placebo. Binciken bai fayyace dalilin wannan bambanci ba, kuma ba za a iya ɗaukar sa a matsayin hujjar kariya ba.

Dalilin da Ya Sa Wannan Sakamako Ke Da Nauyi

Fatan NR a cutar Parkinson ya samo asali ne daga nazarin dabbobi da ƙananan gwaje‑gwaje na farko, ciki har da aikin NADPARK da wani ƙungiya a Norway suka gudanar. Wadannan binciken sun nuna NR na iya ɗaga matakin NAD+ a kwakwalwa kuma zai iya tasiri kan tsarin metabolism. Sai dai, gwaje‑gwajen nan suna da ƙarfi kaɗan kuma ba su yi nufin tantance amfanin lafiyar ɗan adam ba. NOPARK ne ya zo da cikakken gwaji mai ƙarfi don tabbatar da sahihancin sakamakon.

Dole ne a ambata cewa wasu daga cikin masu binciken suna da haƙƙin mallakar fasaha (patent) kan amfani da NR don cutar Parkinson, wanda kamfanin Niagen Bioscience (tsohon ChromaDex) ke da lasisi a kai. Wannan na iya ƙara damuwa kan yuwuwar son kai (conflict of interest), duk da cewa tsarin gwajin – raba‑raba da placebo, tabbatar da cutar ta hanyar hoton hoto, da tsayar da manufa tun farko – yana da ƙarfi sosai.

Me Wannan Ke Nufi A Garen Ku?

Kada ku fara amfani da NR da kanku. Gwajin da ya fi ƙarfi da ake da shi ya nuna babu fa'ida, kuma akwai alamar tsananta ciwon a 1 000 mg a rana tsawon shekara guda.
Idan kuna riga kun fara sha, ku tattauna da likitan ku. Kada ku daina ko ku canza magungunan da aka ba ku da kanku.
Kwayoyin kariya ba su maye gurbin maganin dopamine ko kulawar da aka saba ba.

Idan kuna amfani da NR ko NMN don tsawaita rayuwa gaba ɗaya

Wannan gwaji an gudanar da shi ne a cikin mutanen da ke da cutar Parkinson a matakin farko, ba a tsakanin masu lafiya ba. Ba ya nuni da cewa NR na cutar da mutanen da ba su da cuta.
Sakamakon yana saka darajar ikirarin “ɗaga NAD+ kuma kare kwakwalwa” a ƙasa. Idan NR ba ta iya taimakawa ko da a cutar da NAD+ ke matsayin manufa, to ikirarin kariya a cikin mutane masu lafiya ba su da ƙarfi.
NMN ba a gwada shi a wannan bincike ba, don haka ba za a iya ɗaukar wannan sakamako kai tsaye ga NMN ba. Kimiyyar tsarin yana nuna iri ɗaya, don haka tambayoyi suna da ma'ana.
Adadin da lokacin amfani: Gwajin ya yi amfani da 500 mg sau biyu a rana tsawon makonni 52. Yawancin samfuran da ake sayarwa a kasuwa suna ba da ƙananan ƙima, don haka wannan gwaji ba ya ba da hujja ga yanayin amfani na yau da kullum.

Waɗanda Zasu Iya Tsallake NR

Kowane mutum da ke da cutar Parkinson ko yana da tarihin iyali mai ƙarfi na cutar, kuma ke tunanin amfani da NR a matsayin kariya ko gyara cuta.

Waɗanda Zasu Iya Ci Gaba da Amfani

Mutanen da ke sha saboda wasu dalilai (misali, “anti‑aging”) – su tattauna da likita, musamman idan suke da wata cuta ko suna shan wasu magunguna.

Karshe

NOPARK ya kasance misalin yadda wani magani da aka ɗauka a matsayin zakaran gwaji a cikin dabbobi ya kasa cimma manufa a cikin mutane. Tasirin ya kasance ƙanƙanta, ba ya kai matakin da ake buƙata don zama mai ma'ana a fannin likitanci, haɗari masu tsanani sun fi ƙasa a rukuni na NR, kuma gwajin ya shafi cutar Parkinson a matakin farko kawai. A takaice, NR ba ta kawo wani canji da zai iya canza tafiyar cutar ba.